Abstract
Cellular targeting and intracellular delivery of small interfering RNA (siRNA) remain a critical barrier to the clinical application of RNA interference. This chapter provides an overview of various delivery agents employing protein ligands mediating cell-specific delivery of siRNA. Specifically, the chapter details methodologies for the conjugation of antibody or peptide ligands to i) the cationic peptide-oligo-9-arginine (ii) the polymer poly(lactic-co-glycolic acid) (PLGA) and (iii) a lipid-vesicle (liposome).
Copyright © 2012 Elsevier Inc. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Antibodies / chemistry
-
Antibodies / metabolism*
-
Cell Line, Tumor
-
Cross-Linking Reagents / chemistry
-
Drug Carriers / chemistry
-
Drug Carriers / metabolism*
-
Humans
-
Lactic Acid / chemistry
-
Liposomes / chemistry
-
Molecular Targeted Therapy*
-
Neoplasms / genetics
-
Neoplasms / metabolism
-
Neoplasms / pathology
-
Neoplasms / therapy*
-
Oligopeptides / chemistry
-
Oligopeptides / metabolism*
-
Organ Specificity
-
Polyglycolic Acid / chemistry
-
Polylactic Acid-Polyglycolic Acid Copolymer
-
RNA Interference
-
RNA, Small Interfering / genetics
-
RNA, Small Interfering / metabolism*
-
RNA, Small Interfering / pharmacology
-
Transfection / methods*
Substances
-
Antibodies
-
Cross-Linking Reagents
-
Drug Carriers
-
Liposomes
-
Oligopeptides
-
RNA, Small Interfering
-
Polylactic Acid-Polyglycolic Acid Copolymer
-
Polyglycolic Acid
-
Lactic Acid